Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

45.40 +1.17 (+2.65%)
Official Closing Price Updated: 7:00 PM EDT, Aug 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
78 79 Next >
Bristol Myers Squibb’s Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)
From Bristol Myers Squibb
Via Business Wire
Why Is Replimune Stock Trading Lower On Monday?
Replimune stock falls as FDA denies skin cancer drug approval and investors sue over alleged misstatements tied to the IGNYTE trial. 
Via Benzinga
BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth
BioNTech beat Q2 estimates with higher COVID vaccine revenue and reaffirmed 2025 guidance. 
Via Benzinga
Meta, Microsoft Power Wall Street To New Records Despite Inflation Jump: What's Moving Markets Thursday?
A post-earnings surge in Meta Platforms Inc. (NASDAQ:META) and Microsoft Corp. 
Via Benzinga
Topics Economy
Earnings Scheduled For July 31, 2025
 
Via Benzinga
Bristol-Myers Squibb Earnings Preview
 
Via Benzinga
Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas
Via Investor Brand Network
Topics Government
Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas
EQNX::TICKER_START (NASDAQ:SNGX),(NYSE:PFE),(NYSE:MRK),(NYSE:BMY),(NASDAQ:INSM) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Government
This Biotech Stock Could Soar on Upcoming Clinical Data
This weight loss drugmaker may be significantly undervalued right now. 
Via The Motley Fool
Bristol Myers (BMY) Q2 EPS Jumps 36%
Via The Motley Fool
Topics Intellectual Property
Trump Issues 60 Day Ultimatum To US Pharma Giants To Slash Drug Prices: 'If You Refuse To Step Up We Will...'
President Donald Trump has issued a 60-day ultimatum to 17 major pharmaceutical companies, demanding that they lower drug prices in the U.S. or face severe consequences. 
Via Benzinga
Topics Government
Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch
Via Stocktwits
Topics Government
Bristol-Myers Squibb Unusual Options Activity For July 31
 
Via Benzinga
Why Bristol-Myers Squibb (BMY) Stock Is Trading Lower Today
Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) fell 4.2% in the afternoon session after the company lowered its full-year earnings forecast, overshadowing second-quarter results... 
Via StockStory
Topics Intellectual Property World Trade
Bristol-Myers Squibb (NYSE:BMY) Reports Strong Q2, Full-Year Sales Guidance is Optimistic
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q2 CY2025, but sales were flat year on year at $12.27 billion. The company’s full-year revenue... 
Via StockStory
Bristol Myers Cuts Earnings Outlook As Legacy Drugs Face Generic Erosion
Bristol Myers beat Q2 sales expectations but cut its 2025 EPS forecast as strategic charges and legacy product declines weighed on earnings. 
Via Benzinga
Bristol-Myers Squibb Co (NYSE:BMY) Surpasses Q2 2025 Earnings and Revenue Estimates, Shares Rise in Pre-Market Trading
Bristol-Myers Squibb (BMY) beats Q2 2025 revenue and EPS estimates, driving a 2.9% pre-market stock surge. Strong oncology, immunology, and cardiovascular drug sales fuel growth. 
Via Chartmill
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) – A High-Yield Dividend Stock with Strong Profitability and Financial Health
Bristol-Myers Squibb (BMY) offers a high 5.06% dividend yield, strong profitability, and solid financial health, making it a top pick for income investors. Its undervalued stock and consistent payout... 
Via Chartmill
Bristol Myers Squibb Reports Second Quarter Financial Results for 2025
From Bristol Myers Squibb
Via Business Wire
Stock Market Today: S&P 500, Nasdaq To Open Higher After Robust Meta, Microsoft Earnings—Investors Await Apple, Amazon Results
U.S. stock futures rose on Thursday after ending on a mixed note on Wednesday. Futures of major benchmark indices were higher, except for the small-cap gauge Russell 2000. 
Via Benzinga
Topics Stocks
Dow Falls Over 150 Points After Powell's Comments On Rate Cuts: Investor Sentiment Declines, But Fear Index Remains In 'Greed' Zone
US stocks fell on Wednesday, with the Dow dropping over 150 points after Fed Chair Powell's comments. Fear Index remained in Greed zone. 
Via Benzinga
Topics Economy Stocks
Microsoft, Apple And 3 Stocks To Watch Heading Into Thursday
U.S. stock futures up, Apple, Amazon, Meta report strong earnings, Microsoft beats forecast, Bristol-Myers Squibb to release results. 
Via Benzinga
Bristol Myers Squibb: A Stock with Potential Amid Challenges
Via The Motley Fool
Got $500? 3 Blue Chip Dividend Stocks to Buy and Hold Forever
Being a great investor doesn't have to be complicated or expensive. 
Via The Motley Fool
Topics Intellectual Property
3 Low-Volatility Stocks We Find Risky
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. 
Via StockStory
Bristol-Myers Squibb (BMY) Q2 Earnings: What To Expect
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting results this Thursday morning. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical Needs of Patients
From Bristol Myers Squibb
Via Business Wire
Why Is ATAI Life Sciences Stock Trading Lower On Monday?
Recognify's CIAS trial for inidascamine missed its main endpoint but showed positive signals in cognitive domains and had a favorable safety profile. 
Via Benzinga
Biotech Is Booming, and This Undervalued REIT Stands to Gain
Via The Motley Fool
Explore the top gainers and losers within the S&P500 index in today's session.
Let's delve into the developments on the US markets in the middle of the day on Friday. Below, you'll find the top gainers and losers within the S&P500 index during today's session. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
78 79 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.